Andrew John (AJ) Rudowitz


  • Andrew John (AJ) Rudowitz
  • Phone: +1 215 979 1974
    Fax: +1 215 689 2599

    Import to Address Book

  • Duane Morris LLP
    30 South 17th Street
    Philadelphia, PA 19103-4196

Andrew John (AJ) Rudowitz practices in the area of litigation. Mr. Rudowitz is a 2017 summa cum laude graduate of Temple University Beasley School of Law, where he was articles editor of the Temple Law Review, and a graduate of Stonehill College. Prior to entering law school, Mr. Rudowitz was a professional basketball player in Germany for four years. He is proficient in written and spoken German.


  • Temple University Beasley School of Law, J.D., summa cum laude, 2017
    ◦ Articles Editor, Temple Law Review
  • Stonehill College, B.A., 2010


  • Duane Morris LLP

    • Associate, 2017-present

Representative Matters

  • Successfully represented a U.S. company in an eighteen (18) month hearing before the Pennsylvania Gaming Control Board involving complicated legal issues under the Pennsylvania gaming law, comparison of the regulation of a licensee in Hong Kong with the regulation of a registered investment adviser in the United States, as well as a comparison of the regulation of an investment company in the Cayman Islands with the regulation of an investment company in the United States.
  • Represented a former executive of a defunct resort and casino project in defending against a $3 billion suit brought by a Chapter 7 trustee in Miami bankruptcy court alleging the client aided and abetted others in a breach of fiduciary duty that caused the project to fail.
  • Represented Otto Bock HealthCare North America, Inc. in FTC investigation and litigation. FTC Docket No. 9378
  • Represented the President of an information technology staffing firm in criminal prosecution for visa fraud and criminal forfeiture.
  • Represented Virtus Pharmaceuticals, a specialty pharmaceutical company, in a recent mediation against a now defunct contract drug manufacturer and its insurers. Recovered all of Virtus' multi-million dollar losses resulting from a national recall of two drugs made by the manufacturer.